Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1) have been demonstrated to be key regulators of T-cell anti-tumour immune response and are effective targets for immunotherapeutic agents [54,55]. The gene discussed is CTLA4; the disease is neoplasm.